Skip to main content

Table 4 Results of univariate and multivariate analyses of risk factors of delayed nausea among 312 cases with palonosetron receiving MEC

From: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

  Univariate Multivariate
n OR 95% CI P-value OR 95% CI P-value
Age < 75 vs. ≥75 years 312 0.444 0.168 , 1.176 0.102     
Sex Female (vs. Male) 312 1.273 0.724 , 2.239 0.402     
Anti-cancer drug 312           
 L-OHP 178 1.000   ref    1.000   ref   
 CPT11 60 0.396 0.159 , 0.989 0.047 0.505 0.137 , 1.860 0.304
 CBDCA 74 0.983 0.509 , 1.898 0.960 1.769 0.533 , 5.870 0.351
Oral 5-FU 312           
 Nothing 157 1.000   ref    1.000   ref   
 S-1 30 0.812 0.261 , 2.530 0.720 0.671 0.144 , 3.124 0.611
 Capecitabine 125 1.817 1.011 , 3.266 0.046 2.111 0.690 , 6.458 0.190
Additional oral steroid days 2 or 3 (vs. Nothing) 312 0.654 0.370 , 1.156 0.144     
NK1RA (vs. Nothing) 312 1.340 0.715 , 2.513 0.362     
Primary organ 312          
 colorectal cancer 211 1.000   ref        
 gastric cancer 25 n.c.          
 lung cancer 23 1.054 0.371 , 2.998 0.921      
 gynecological cancer 53 1.111 0.539 , 2.291 0.776      
Hb < 10 mg/dl 312 0.719 0.410 , 1.260 0.249     
Neut < 1500/μl 312 0.632 0.181 , 2.207 0.472     
PLT < 7.5 × 104/μl 312 1.535 0.875 , 2.691 0.135     
CRE ≥1.1 mg/dl 312 3.112 0.953 , 10.167 0.060     
AST > 2.5 ULN 312 1.780 0.964 , 3.287 0.066     
ALT > 2.5 ULN 312 2.166 1.122 , 4.180 0.021 2.397 1.153 , 4.984 0.019
Fever elevation > 38 °C 312 0.574 0.127 , 2.595 0.471     
Constipation 312 0.884 0.470 , 1.664 0.702     
Diarrhea 312 1.394 0.729 , 2.666 0.315     
Oral mucositis 312 1.230 0.655 , 2.310 0.520     
Taste alteration 312 1.225 0.685 , 2.190 0.493     
Neuropathy 312 1.804 0.986 , 3.302 0.056     
Eruption 312 1.534 0.875 , 2.690 0.135     
General fatigue 312 3.221 1.729 , 6.000 0.000 2.652 1.380 , 5.097 0.003
NRS ≥1 312 1.125 0.613 , 2.064 0.704     
PS 312           
 0 155 1.000   ref    1.000   ref   
 1 146 1.532 0.853 , 2.752 0.153 1.360 0.723 , 2.558 0.340
 2 11 4.549 1.285 , 16.101 0.019 5.748 1.392 , 23.740 0.016
  1. MEC moderately emetogenic chemotherapy, L-OHP oxaliplatin, CPT-11 irinotecan, CBDCA carboplatin, Hb hemoglobin, Neut neutrophil, PLT platelet, CRE creatine, ULN upper limit of normal, NRS numerical rating scale, PS performance status, OR odds ratio, CI confidence interval